Archived Newsletters

1. 07.28.21 -- Considerations For A More Informed CDMO Selection 7/28/2021

   07/28/21 Outsourced Pharma Newsletter

2. 07.28.21 -- CDMOs "Bumping" Cell And Gene Companies 7/28/2021
   07/28/21 Outsourced Pharma Newsletter
3. 07.28.21 -- CDMOs "Bumping" Cell And Gene Companies 7/28/2021
   07/28/21 Outsourced Pharma Newsletter
4. 07.28.21 -- CDMOs "Bumping" Cell And Gene Companies 7/28/2021
   07/28/21 Outsourced Pharma Newsletter
5. 07.28.21 -- What To Expect From A Remote Inspection — And How To Navigate It 7/28/2021
   07/28/21 Outsourced Pharma Newsletter
6. 07.27.21 -- Biologics: Avoid Complications And Prevent Cost Overruns 7/27/2021
   07/27/21 Outsourced Pharma Newsletter
7. 07.27.21 -- Embarking On The Commercial Manufacturing Journey 7/27/2021

   07/27/21 Outsourced Pharma Newsletter

8. 07.26.21 -- Navigating DSCSA Implementation: Key Requirements & 4 New FDA Guidances 7/26/2021
   07/26/21 Outsourced Pharma Newsletter
9. 07.26.21 -- Recombinant AAV Production: Evaluating Current Manufacturing Platforms 7/26/2021
   07/26/21 Outsourced Pharma Newsletter
10. 07.26.21 -- FDA's Revamped Purple Book: Patent Transparency For Biologics & Biosimilars 7/26/2021
    07/26/21 Outsourced Pharma Newsletter